The COVID-19 pandemic has profound adverse effects on the population on dialysis.
Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality …

Cellular and humoral immunity exhibit dynamic adaptation to the mutating SARS-CoV-2
virus. It is noteworthy that immune responses differ significantly, influenced by whether a …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and
infection outcomes were evaluated in 2,686 patients with varying immune-suppressive …

Background and objectives Patients receiving hemodialysis are at high risk from coronavirus
disease 2019 (COVID-19) and demonstrate impaired immune responses to vaccines. There …

Omicron, the SARS-CoV-2 B. 1.1. 529 variant of concern (VOC), was first detected in
southern Africa in November, 2021, and its BA. 1 sublineage is now dominant in the UK …

A robust serological test is required to detect neutralizing antibodies (NAbs) against severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A nanomaterial‐coupled …

The critical question is how well existing vaccines will protect clinically extremely vulnerable
groups against infection. In the UK, the COVID-19 death rate for in-centre haemodialysis (IC …

Background Kidney disease is a key risk factor for COVID-19-related mortality and
suboptimal vaccine response. Optimising vaccination strategies is essential to reduce the …

Results A total of 1121 in-center hemodialysis patients were included in the analysis; all
patients underwent weekly screening for SARS-CoV-2 infection via reverse transcriptase …